A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Public ClinicalTrials.gov record NCT06109272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment
Study identification
- NCT ID
- NCT06109272
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 660 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Bevacizumab Drug
- Budigalimab Drug
- Durvalumab Drug
- Livmoniplimab Drug
- Tremelimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2024
- Primary completion
- Aug 31, 2030
- Completion
- Aug 31, 2030
- Last update posted
- Aug 14, 2025
2024 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 261468 | Duarte | California | 91010 | Recruiting |
| City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669 | Irvine | California | 92618 | Recruiting |
| UC Irvine /ID# 255673 | Orange | California | 92868 | Recruiting |
| The University of Chicago Medical Center /ID# 255674 | Chicago | Illinois | 60637-1443 | Recruiting |
| Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830 | Merriam | Kansas | 66204 | Completed |
| Norton Cancer Institute /ID# 260775 | Louisville | Kentucky | 40217-1395 | Recruiting |
| Henry Ford Hospital /ID# 255803 | Detroit | Michigan | 48202 | Recruiting |
| Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041 | Saint Louis Park | Minnesota | 55416 | Recruiting |
| Washington University-School of Medicine /ID# 255720 | St Louis | Missouri | 63110 | Recruiting |
| Texas Oncology - Abilene - Antilley Road /ID# 265820 | Abilene | Texas | 79606 | Recruiting |
| Texas Oncology - Dallas - Worth Street /ID# 265806 | Dallas | Texas | 75246 | Recruiting |
| Baylor Scott and White Research Institute /ID# 260853 | Dallas | Texas | 76508-0001 | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia /ID# 265834 | Roanoke | Virginia | 98684 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06109272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06109272 live on ClinicalTrials.gov.